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Dear Editor,
Immunotherapy inhibiting the signaling interaction 
between programmed death 1 (PD1) and its ligand 
programmed death-ligand 1 (PD-L1) is rapidly expanding 
as an established or experimental oncological treatment 
for several types of solid tumors, especially melanoma and 
non-small cell lung carcinoma (NSCLC) (Gandini  et  al. 
2016) as well as for various hematopoietic malignancies, 
notably Hodgkin’s lymphomas (HL). PD1 is one of the 
immune response-regulating checkpoints: interaction 
between PD1 on T-cells and PD-L1 on cancer cells 
provides a mechanism for cancer cells to evade proper 
recognition as foreign and thus escape attack by the 
immune system. Currently, several monoclonal anti-PD1 
or anti-PD-L1 antibodies that inhibit this interaction 
‘–checkpoint inhibitors’ – are approved by the FDA for 
clinical use; the first was pembrolizumab, an anti-PD1 
agent, initially approved for the treatment of advanced 
melanoma and currently also for advanced NSCLC and 
for recurrent or metastatic head and neck squamous cell 
carcinoma (http://www.accessdata.fda.gov/scripts/cder/
daf/index.cfm?event=overview.process&applno=125514; 
accessed 17.03.2017). The second anti-PD1 agent 
approved was nivolumab, initially approved for the 
treatment of advanced melanoma and currently also for 
several other tumors such as advanced NSCLC; metastatic 
renal cell carcinoma; HL; recurrent or metastatic head and 
neck squamous cell carcinoma; and previously-treated 
locally advanced or metastatic urothelial carcinoma 
(http://www.accessdata.fda.gov/scripts/cder/daf/index.
cfm?event=overview.process&ApplNo=125554; accessed 
17.03.2017). Atezolizumab is currently the only approved 
anti-PD-L1 agent; it is in use for urothelial carcinoma 
and for metastatic NSCLC (https://www.fda.gov/drugs/
informationondrugs/approveddrugs/ucm525780.htm; 
accessed 17.03.2017). 
In several cancer types where these checkpoint 
inhibitors are used, clinical responses rates as high as 30% 
to 50% have been demonstrated (Gandini  et  al. 2016). 
When considering such molecular-targeted therapies for an 
individual patient, identification of predictive biomarkers 
may be useful for patient selection to improve treatment 
efficacy while avoiding unjustified secondary effects and 
also making rational use of healthcare resources. Thus, 
several studies have investigated the immunohistochemical 
expression of PD1 and PD-L1 in both tumor cells and 
tumor-infiltrating immune cells, showing that malignant 
cells are PD-L1-positive in a variable proportion of HL, 
melanoma, glioblastoma, NSCLC and head and neck, 
breast, ovarian, renal, pancreatic and esophageal carcinoma 
(Chowdhury et al. 2016).
Regarding thyroid tumors, a few papers have reported 
on PD-L1 expression in thyroid (Cunha  et  al. 2013, 
Angell  et  al. 2014, Wu  et  al. 2015, Bastman  et  al. 2016, 
Chowdhury et al. 2016, Ahn et al. 2017, Shi et al. 2017). 
With the exception of two studies on anaplastic 
(undifferentiated) thyroid carcinoma (ATC) (Wu  et  al. 
2015, Ahn  et  al. 2017), these studies were focused 
primarily on follicular cell-derived tumors (differentiated 
thyroid carcinoma, DTC), including papillary thyroid 
carcinoma (PTC), follicular thyroid carcinoma (FTC) 
and poorly differentiated thyroid carcinoma (PDTC) 
(Cunha et al. 2013, Angell et al. 2014, Bastman et al. 2016, 
Chowdhury et al. 2016, Ahn et al. 2017, Shi et al. 2017). 
For these tumors (i.e., DTC), immunotherapy could be 
considered in the small minority of cases that are classed 
as refractory to radioiodine treatment.
The latest study by Ahn and coworkers recently 
published in Endocrine-Related Cancer used tissue 
microarrays to investigate 407 primary thyroid cancers 
for PD-L1 expression using the monoclonal antibody 
SP142 (Ahn et al. 2017). PD-L1 was found to be expressed 
in cancer cells in 6.1% of PTC, 7.6% of FTC and 22.2% 
of ATC; regarding immune cells, they were positive 
for PD-L1 in 28.5% of PTC, 9.1% of FTC and 11.1% of 
ATC. In general, the more aggressive the tumor, the 
higher the expression of PD-L1, yet no significant 
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association was found between PD-L1 expression 
and disease progression, disease-free survival or other 
clinicopathological parameters. Interestingly, in a pilot 
trial of pembrolizumab in DTC, only a limited percentage 
of partial responses was observed (9.1%, 2/22 patients) 
(Mehnert  et  al. 2016). Nevertheless, other trials to test 
checkpoints inhibitors (https://clinicaltrials.gov/ct2/
show/NCT03012620; https://clinicaltrials.gov/ct2/show/
NCT02458638; accessed 17.03.2017) are ongoing for 
radioiodine-refractory DTC. Due to its distinct origin 
from parafollicular cells, medullary thyroid carcinoma 
(MTC) is always refractory to radioiodine treatment. 
Even though the aforementioned clinical trials will 
also test the effectiveness of targeting the PD1/PD-L1 
system in MTC, to the best of our knowledge there are 
no reports on the expression of PD-L1 in MTC. We thus 
decided to investigate this question in all MTC patients 
operated in our tertiary center over a twenty-year period 
(1996–2016). Using an anti-PD-L1 rabbit monoclonal 
antibody (clone SP263, ready to use, Ventana Medical 
Systems, Tucson, AZ, USA), we assessed PD-L1 expression 
in both tumor cells and tumor-infiltrating immune cells 
in the tumor specimens (complete histological sections, 
not tissue microarray). The staining was performed with 
the BenchMark automated immunostainer (Ventana 
Medical Systems, Tucson, AZ, USA). We scored tumor cells 
expressing PD-L1 as a percentage of total tumor cells; we 
scored tumor-infiltrating immune cells expressing PD-L1 
as a percentage of positive cells within the tumor area. 
We considered as positive only the membranous pattern, 
and not the cytoplasmic one, because PD-L1 is functional 
as a transmembrane protein. The threshold to consider 
the staining as positive was a percentage of stained cells 
>1%; for positive cases; the percentage of stained cell was 
recorded. As controls we used placenta and benign tonsil 
tissues (Fig. 1A).
Figure 1
PD-L1 expression in medullary thyroid carcinoma. A. Benign tonsil tissue was used as positive control: on the right side of the picture, the reticulated 
crypt epithelial cells show strong membranous positivity for PD-L1; on the left side, some lymphocytes and macrophages in germinal centers show weak 
membranous positivity (PD-L1 immunostain, ×200). B. Focal and membranous expression for PD-L1 in malignant cells in case n° 10. The overall expression 
in malignant cells was scored at 5% (PD-L1 immunostain, ×400). C. One of the two cases showing PD-L1 positivity in the lymphocytic infiltrate  
(case n° 12); PD-L1 was expressed by reactive follicular cells (arrows) and was not expressed by malignant C-cells (asterisks) (PD-L1 immunostain, ×200).
Table 1 Clinicopathological data and PD-L1 expression in malignant cells and immune cells.
 
Patient n°
 
Sex/age, years
Type of initial 
thyroidectomy
 
Size, cm
 
pT
 
pN
PD-L1 expression, % 
(malignant cells)
PD-L1 expression, % 
(immune cells)
Status and length of 
follow-up (years)
1 M/47 Total 3.2 3 1b <1 0 Alive (1,0)
2 F/58 Total 4 2 0 0 0 Alive (1,4)
3 M/47 Hemi 2.1 2 0 <1 0 Alive (6,5)
4 F/45 Total 6.2 3 1a 1 0 Dead (0,5)
5 M/61 Total 4.5 3 1b <1 0 Dead (6,7)
5 bis*   1.9   <1 0  
6 M/71 Total 1.5 1b 1b 1 0 Dead (1,6)
7 F/40 Total 3 3 1 0 0 Lost to follow up
8 F/64 Total 0.6 1a 0 0 0 Alive (6,5)
9 F/34 Total 2.1 3 1 0 0 Dead (9,1)
10 F/52 Hemi 0.8 1a x 5 0 Alive (11,5)
11 F/69 Total 3.5 4a 1b 1 1 Alive (6,5)
12 F/21 Total 4.8 3 x <1 2 Dead (5,10)
13 F/45 Hemi 8 3 x 0 0 Lost to follow up
14 F/37 Total 2.9 2 1b 0 0 Alive with MTS (8,6)
15 F/58 Total 1.3 1b 0 0 0 Alive (0,5)
16 M/32 Hemi 1.5 1b x 0 0 Dead (13,7)
*Lymph node metastasis of patient 5.
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Sixteen cases of MTC were recovered over the study 
period: 5 males and 11 females with a median age of 
47  years (Table  1). All but one cases scored negatively 
in the tumor cells. The patient who showed positive 
cells (5%) was a female, and was still alive at the last 
follow-up; she had a microcarcinoma (0.8 cm) (Fig. 1B). 
Regarding tumor-infiltrating immune cells, of which 
there are generally few in MTC (including in this series), 
PD-L1 was not expressed in all cases but two, with 1% 
and 2% of positivity. Interestingly, the latter sample 
also showed reactive follicles within the MTC: these 
were elongated and lined by thyreocytes with abundant 
cytoplasm, evident nucleoli and, notably, membranous 
positivity for PD-L1 (Fig. 1C). No correlation was evident 
between PD-L1 expression and clinicopathological stage 
or survival in our series.
Our results showing almost no expression of PD-L1 in 
MTC cells and accompanying inflammatory cells should 
be replicated on a larger scale in other centers. They are 
indicative of near uniform absence of the expression of 
PD-L1 in this aggressive thyroid tumor subtype. The fact 
that we evaluated PD-L1 expression in a large portion of 
each tumor’s surface (as opposed to tissue microarrays 
in the study by Ahn  et  al.) confers robustness to the 
present work. Another difference with the study by Ahn 
and coworkers is that we used a different monoclonal 
antibody, namely SP263; however, it has been shown that 
the results obtained with these two antibodies are highly 
correlated (Gaule et al. 2017).
Like DTC, MTC has one of the lowest mutational 
loads and neo-antigen repertoires among all solid tumors 
(Agrawal  et  al. 2013). Moreover, as mentioned above, 
on histological examination, MTC usually has very few 
accompanying inflammatory cells. These reasons may 
account for the very low expression of PD-L1 in our 
series. Nevertheless, experience with melanoma (a tumor 
more immunogenic and with more tumor-infiltrating 
immune cells than MTC) suggests that immunotherapy 
against checkpoint inhibitors can be clinically beneficial 
even in cases with low expression of PD-L1. Thus, 
definitive answers regarding the utility of PD1/PD-L1 
immunophenotyping in MTC (as well as in DTC and 
ATC) and of the use of checkpoint inhibitors in the 
treatment of thyroid neoplasms must await the results of 
the respective ongoing clinical trials, provided that these 
trials will perform immunohistochemistry for PD1/PD-L1.
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